Biogen Inc. (BIIB) revenue by segment
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3058% above fair value
$249.59+2.46 (+1.00%)
Close on Nov 20, 2026Market cap $36.89BP/E 106.7Yield –
Doanh thu theo bộ phận của Biogen Inc.
Theo bộ phận kinh doanh
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $9.89B | $9.68B | $9.84B | $10.17B | – | – | – | – | – | – | 100.0% | +2.2% |
| Rest of world | – | – | – | – | – | – | – | – | $3.34B | $2.77B | – | – |
| U. S. | – | – | – | – | – | – | – | – | $7.02B | $7.05B | – | – |
Theo sản phẩm hoặc dịch vụ
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $7.12B | $7.21B | $7.25B | $7.99B | $8.85B | $10.69B | $11.38B | $10.89B | $10.35B | $9.82B | 72.0% | -1.3% |
| MS Product Revenues | $4.04B | $4.35B | $4.66B | $5.43B | $6.10B | $7.83B | $8.53B | $8.60B | $8.98B | $8.82B | 40.8% | -7.1% |
| Rare Disease Product Revenue | $2.15B | $1.99B | $1.80B | $1.79B | $1.91B | – | – | – | – | – | 21.8% | +8.4% |
| Revenue from anti-CD20 therapeutic programs | $1.86B | $1.75B | $1.69B | $1.70B | $1.66B | $1.98B | $2.29B | $1.98B | $1.56B | $1.31B | 18.8% | +6.3% |
| TYSABRI | $1.67B | $1.72B | $1.88B | $2.03B | $2.06B | $1.95B | $1.89B | $1.86B | $1.97B | $1.96B | 16.8% | -2.9% |
| SPINRAZA | $1.55B | $1.57B | $1.74B | $1.79B | $1.91B | $2.05B | $2.10B | $1.72B | $883.70M | $4.60M | 15.6% | -1.7% |
| Fumarate | $1.43B | $1.60B | $1.59B | $2.00B | $2.36B | $3.91B | $4.44B | $4.27B | – | – | 14.4% | -10.6% |
| Royalty Attributed To OCREVUS | $1.41B | $1.34B | $1.27B | $1.14B | $991.70M | $845.40M | – | – | – | – | 14.3% | +5.6% |
| Interferon | $945.60M | $968.00M | $1.11B | $1.31B | $1.57B | $1.88B | $2.10B | $2.36B | $2.65B | $2.80B | 9.6% | -2.3% |
| VUMERITY | $746.80M | $628.00M | $576.30M | $553.40M | $410.40M | $64.30M | $5.50M | $0 | $0 | – | 7.6% | +18.9% |
| Contract manufacturing, royalty and other revenue | $732.90M | $652.60M | $899.30M | $485.10M | $476.30M | $774.60M | $707.70M | $585.90M | $360.00M | $316.40M | 7.4% | +12.3% |
| Biosimilars | $729.10M | $793.10M | $770.00M | $751.10M | $831.10M | $795.80M | $738.30M | $545.10M | $379.80M | $100.70M | 7.4% | -8.1% |
| AVONEX | $695.50M | $707.50M | $811.00M | $973.50M | $1.21B | $1.49B | – | – | $2.15B | $2.31B | 7.0% | -1.7% |
| TECFIDERA | $679.70M | $967.10M | $1.01B | $1.44B | $1.95B | $3.84B | $4.43B | $4.27B | $4.21B | $3.97B | 6.9% | -29.7% |
| Contract manufacturing revenue | $679.40M | $592.10M | $848.20M | $417.70M | $427.70M | $719.10M | – | – | – | – | 6.9% | +14.7% |
| SKYCLARYS | $520.50M | $382.50M | $55.90M | $0 | $0 | – | – | – | – | – | 5.3% | +36.1% |
| BENEPALI | $453.20M | $479.10M | $438.80M | $441.00M | $498.30M | $481.60M | $486.20M | $485.20M | $370.80M | $100.60M | 4.6% | -5.4% |
| PLEGRIDY | $250.10M | $260.50M | $294.70M | $331.90M | $357.40M | $385.60M | – | – | $494.30M | $481.70M | 2.5% | -4.0% |
| Other | $197.20M | $82.50M | $11.80M | $13.00M | $14.00M | – | – | – | – | – | 2.0% | +139.0% |
| ZURZUVAE | $195.10M | $72.20M | $1.60M | $0 | – | – | – | – | – | – | 2.0% | +170.2% |
| IMRALDI | $190.20M | $213.10M | $222.10M | $224.50M | $233.40M | $216.30M | $184.00M | $16.70M | $0 | $0 | 1.9% | -10.7% |
| Alzheimer's Collaboration | $177.70M | $59.90M | $0 | $0 | – | – | – | – | – | – | 1.8% | +196.7% |
| QALSODY | $86.90M | $32.40M | $5.90M | $0 | $0 | – | – | – | – | – | 0.9% | +168.2% |
| Royalty and other revenue | $53.50M | $60.50M | $51.10M | $67.40M | $48.60M | $55.50M | $17.00M | $38.70M | $69.80M | $46.50M | 0.5% | -11.6% |
| FLIXABI | $52.60M | $63.20M | $77.40M | $81.30M | $99.40M | $97.90M | $68.10M | $43.20M | $9.00M | $100.00K | 0.5% | -16.8% |
| BYOOVIZ | $32.40M | $36.60M | $31.70M | $4.30M | $0 | $0 | – | – | – | – | 0.3% | -11.5% |
| FUMADERM And ADUHELM | $2.10M | $10.30M | $10.20M | $13.00M | – | – | – | – | – | – | 0.0% | -79.6% |
| FAMPYRA | $1.40M | $71.70M | $90.50M | $96.60M | $105.20M | $103.10M | $97.10M | $92.70M | $91.60M | $84.90M | 0.0% | -98.0% |
| TOFIDENCE | $700.00K | $1.10M | $0 | $0 | – | – | – | – | – | – | 0.0% | -36.4% |
| ADUHELM | – | – | – | $4.80M | $3.00M | $0 | $0 | – | – | – | – | – |
| FUMADERM | – | – | – | $8.20M | $11.00M | $12.20M | $15.20M | $22.30M | $39.60M | $45.90M | – | – |
| Other corporate revenues | – | – | – | – | $427.70M | $719.10M | $584.50M | $459.40M | $253.70M | $230.60M | – | – |
| ZINBRYTA | – | – | – | – | – | $0 | $0 | $1.40M | $52.70M | $7.80M | – | – |
| ELOCTATE | – | – | – | – | – | – | $0 | $0 | $48.40M | $513.20M | – | – |
| Hemophilia Products | – | – | – | – | – | – | $0 | $0 | $74.40M | $846.90M | – | – |
| ALPROLIX | – | – | – | – | – | – | $0 | $0 | $26.00M | $333.70M | – | – |
Theo khu vực
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other | – | – | – | – | – | – | – | – | $332.70M | $313.00M | – | – |
| U. S. | – | – | – | – | – | – | – | – | $7.02B | $7.05B | – | – |
| Germany | – | – | – | – | – | – | – | – | – | $703.70M | – | – |
| Asia | – | – | – | – | – | – | – | – | $160.10M | $217.30M | – | – |
| Europe | – | – | – | – | – | – | – | – | $2.84B | $2.24B | – | – |
| Italy | – | – | – | – | – | – | – | – | – | $42.00M | – | – |
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của Biogen (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của Biogen, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
See a number that looks wrong?